Data Supports Continuous Glucose Monitoring (CGM) to Reduce Need for Self-Monitoring of Blood Glucose for Type 1 Diabetes

NEW ORLEANS, June 13, 2016 /PRNewswire/ -- Data adding to the body of evidence on the benefits of continuous glucose monitoring (CGM) were presented in the poster session at the 76^th Scientific Sessions of the American Diabetes Association. The studies, which were conducted by researchers at Dexcom, Inc., (NASDAQ:DXCM), suggest that CGM technology has improved accuracy and reliability, and likely will build trust in the devices, as well as encourage patients to use CGM as their primary source for glucose information. The data also suggests that patients who customize their CGM alert settings are more likely to achieve better glycemic control, and patients across a range of ages can reduce self-monitoring of blood glucose (SMBG) frequency with CGM therapy.

"We are delighted that the data presented at this year's American Diabetes Association have shown continuous benefits and value-added functionality of our CGM systems," said Kevin Sayer, President and CEO, Dexcom. "With CGM, diabetes is becoming much more manageable while improving the quality of everyday life for millions of people with type 1 diabetes."

About the Studies

Patient Data from RT-CGM Suggests Use of Threshold Alerts Impacts Glycemic Control2  
This study was an analysis of real-world data from patients' continuous glucose monitoring (CGM) devices, and included a total of 17.5 million data records. Even though the benefit of CGM to manage diabetes is well known, one thing that hadn't been fully investigated was the impact of user-controlled alert levels.

Researchers identified the most-frequently chosen patient-set levels for low-glucose alerts (LGL) and high-glucose alerts (HGL), as well as the average daily screen views. They also looked at the average and standard deviation of CGM glucose as a measure of glycemic variability.

Key Results:

• The researchers found that custom, user-defined LGL and HGL alerts on the CGM device help define the user's average glucose variation.  For example: 1) average glucose level and glucose variation were correlated with the most-commonly set alerts for LGL and HGL; 2) patients who were more actively involved with their CGM devices—based on the number times they viewed their screen—had a lower average glucose and less variation; 3) glucose average and variation decreased when patients set their LGL alert lower and increased when patients set their HGL alert higher.

Clinical Use of CGM Results in Reduced Frequency of BGM1  
In this review of existing data, Dexcom analyzed 11 randomized controlled studies that were published after 2008. The studies evaluated the effect of initiation of CGM on changes in the frequency of blood glucose management (BGM). As part of the same review, the company also looked at longitudinal data from the T1 Diabetes Exchange, a network of 67 adult and pediatric endocrine clinics, on SMBG before and after a CGM intervention.

Key Results:

• Five of the 11 studies recorded BGM frequency. All five reported reductions in frequency of BGM associated with CGM use. The biggest impact on reduction of BGM was duration of CGM use, with those using CGM more than three months showing the greatest reductions.
  
  In addition, survey data conducted before and 12 months after initiating CGM revealed reductions in SMBG use in 78 percent (58/74) of respondents. Most importantly, improvements in glucose control, reductions in frequency and duration of hypoglycemia, and improvements in quality-of-life and reduced fear of hypoglycemia occurred in conjunction with the reductions in BGM frequency.

"Taken collectively, the data on the Dexcom CGM presented strengthens the scientific foundation for continuous glucose monitoring," said Tomas Walker, Certified Diabetes Educator, study author, director of clinical projects for Dexcom. "Current CGM monitoring technology has improved accuracy and reliability, and it is likely this will stimulate greater trust in—and therefore greater use of—the CGM device."

About Dexcom, Inc.

Dexcom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) products and tools for adult and pediatric patients.  With exceptional performance, patient comfort and lifestyle flexibility at the heart of its technology, users have consistently ranked Dexcom highest in customer satisfaction and loyalty. For more information on the Dexcom CGM, visit www.dexcom.com.

CONSUMER CONTACT:
Caren Begun
201-396-8551
[email protected]

INVESTOR CONTACT:
Steven Pacelli
858-200-0200

To view multimedia assets, please visit:  http://www.dexcom.com/media http://www.multimedianewscenter.com/dexcom/dexcom-media-portal.

References

1. Walker, TC, Price DA, Leone KJ. Clinical Use of CGM Results in Reduced Frequency of BGM. Presented at the 76^th Scientific Sessions of the American Diabetes Association, New Orleans, Louisiana. June 12, 2016.
2. Nakamura K, Walker T, Balo A. Patient Data from RT-CGM Suggests Use of Threshold Alerts Impacts Glycemic Control. Presented at the 76^th Scientific Sessions of the American Diabetes Association, New Orleans, Louisiana. June 12, 2016.

Logo - http://photos.prnewswire.com/prnh/20150811/257482LOGO

SOURCE Dexcom, Inc.